fda pulling semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know FDA is moving to restrict

Lets have a conversation

By reducing the number of LDL receptors (LDLR) on the surface of liver cells, PCSK9 leads to the accumulation of LDL-C, increasing the risk of CVDs

While Whole Health Rx services are available throughout most of the United States, certain states have laws that prevent clinicians from writing prescriptions without a live consultation and/or lab work

This broader tissue distribution is particularly relevant for researchers designing cell-type-specific binding or functional assays, as the off-target receptor panel for retatrutide is wider than for either semaglutide or tirzepatide

doi: 10.1111/1751-2980.13210, 11

Informed consent For this type of study, consent is not required